Dep2 and its uses in major depressive disorder and other related disorders
Inventors
Katz, David A. • Packer, Jeremy C. • Bhathena, Anahita • Neff, Christopher • Abkevich, Victor • Shattuck, Donna • Jammulapati, Srikanth
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8933209-B2
Publication Date
2015-01-13
Expiration Date
Abstract
The present invention relates to DEP2, as well as other proteins, and their uses in connection with the treatment of major depression or related disorders.
Core Innovation
The patent relates to DEP2 gene locus associated with major depressive disorder and introduces DEP2-1 as a naturally occurring transcript. DEP2-1 is identified as having two coding regions encoding Dep2-1a and Dep2-1b, and the disclosure further includes multiple naturally occurring DEP2-1 splice variants.
The disclosure provides sequence and identity scope for nucleic acids and encoded proteins, including isolated nucleic acid molecules, nucleic acid segments, and complements within specified identity and length constraints. The nucleic acids and encoded proteins are described in the context of defined segments of SEQ ID NO:2 and corresponding complements with identical length.
The patent additionally describes modulation of DEP2 expression and the use of DEP2-related nucleic acids and proteins in detection and characterization. It frames DEP2 as a depression susceptibility gene using linkage and association analysis, including conditionality on HTR1A, and supports utility for genotype-based diagnosis, prognosis, response prediction, DEP2 mRNA and protein quantification, and screening for compositions binding or modulating DEP2-encoded proteins.
Claims Coverage
The supplied material includes one independent claim directed to isolated nucleic acid molecules defined by specific nucleotide segments of SEQ ID NO:2 and corresponding complements with identical length. The claim is limited to two distinct sequence-range selections and does not include additional independent-claim inventive features beyond the sequence selection and complement definition.
Isolated nucleic acid selected by defined segments of SEQ ID NO:2
An isolated nucleic acid molecule selected from nucleic acids consisting of nucleotides 352 to 771 of SEQ ID NO:2 or nucleic acids consisting of nucleotides 812 to 1162 of SEQ ID NO:2.
Complement nucleic acids with identical length
The isolated nucleic acid molecule also includes the complement of the 352 to 771 segment of SEQ ID NO:2 and the complement of the 812 to 1162 segment of SEQ ID NO:2, wherein each complement is identical in length to its corresponding segment.
Overall, the independent claim centers on isolated nucleic acid molecules defined specifically by two SEQ ID NO:2 nucleotide ranges and the complements of those ranges that preserve identical segment length.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?